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Abstract: Advanced or metastatic gastric cancer constitutes the majority of patients in clinical 
practice. In North America, about 70% of cases are advanced or metastatic when diagnosed, 
which is higher than the 50% reported in Japan. This difference in presentation is reflected in 
5-year overall survival, which is about 20% in North America and 40%–60% in Japan. Despite 
numerous efforts of randomized studies on advanced gastric cancer, no globally accepted stan-
dard regimen has yet been established. Systemic chemotherapy provides palliation and prolongs 
survival, but the prognosis remains poor. Several monotherapies and combined regimens are 
currently available and vary around the world. Additionally, several molecular targeting agents 
are under evaluation in international randomized studies. Human epidermal growth factor 
receptor-2 (HER-2) is overexpressed or amplified in approximately 22% of patients with gastric 
cancer. Trastuzumab, a recombinant humanized anti-HER-2 monoclonal antibody, is the first 
biological therapy that has showed a survival improvement by nearly three months (reduced 
risk of death by 26%). Therefore, trastuzumab in combination with cisplatin is a reasonable 
treatment option for patients with advanced gastric cancer who are HER-2 positive. This paper 
will focus on trastuzumab, its chemical and pharmacological characteristics, and the relevant 
efficacy, safety, and tolerability studies.
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Management issues in stomach cancer
Gastric cancer is a cause of considerable morbidity and mortality the second leading 
cause of cancer-related death, and the third most common malignancy worldwide.1 In 
the US, it was estimated that there would be 21,000 new cases and 10,570 deaths from 
gastric cancer in 2010.1 In Japan, there are more than 100,000 new cases diagnosed 
and 50,000 who die annually.2 In Western countries, most newly diagnosed cases 
(73%) will present in the advanced stages when gastric cancer is incurable, having a 
median survival of less than 1 year. Although 52% of gastric cancer cases in Japan are 
diagnosed at an early stage, this fact may be related to mass screening.3,4
Fluoropyrimidines, platinums, taxanes, and irinotecan are considered the main 
active cytotoxic agents for advanced gastric cancer. Palliative chemotherapy for 
advanced or metastatic gastric cancer offers significant advantages in selected fit 
patients, including increased survival, symptom control, and quality of life, compared 
with best supportive care alone.5–9 Systematic review showed that the overall survival 
benefit of chemotherapy over best supportive care was six months (hazards ratio 
[HR] 0.39, 95% confidence interval [CI]: 0.28–0.52). A three-drug regimen includ-
ing 5-flurouracil, anthracyclines, and cisplatin has showed the best survival results, 
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with an HR of 0.83 (95% CI: 0.74–0.93) over single-agent 
5-flurouracil-based chemotherapy. ECF (epirubicin + 
cisplatin + infusional 5-fluoruracil) response rates are 40%, 
with a median survival of 9.4 months and 40% of patients 
alive at 1 year.10 When oxaliplatin is substituted for cisplatin, 
and capecitabine for 5-flurouracil (EOX), response rates 
are 48%, median survival 11.2 months, and 1-year survival 
48%. Interestingly, thromboembolic events were significantly 
higher in cisplatin groups than in oxaliplatin groups   (15.1 
versus 7.6%, P , 0.001).11
Docetaxel combined with cisplatin ± 5-fluorouracil 
(DCF) has better response rates, longer progression-free 
survival, and a small survival advantage compared with cis-
platin + 5-fluorouracil (9.2 versus 8.6 months, P = 0.02).12,13 
However, in patients older than 65 years, increased toxicity of 
neutropenic infection and diarrhea has been seen. Irinotecan 
is also an active drug for advanced gastric cancer, although 
no improvement in survival has been demonstrated in ran-
domized trials.14–16 It may be a more appropriate choice than 
cisplatin + 5-fluorouracil, given its better tolerance. DCF and 
5-fluorouracil plus irinotecan regimens have not been directly 
compared against ECF.
Tegafur, a 5-fluorouracil prodrug, is mainly used in Japan. 
Phase III trials have demonstrated that tegafur is not infe-
rior to 5-fluorouracil in overall survival, and it is associated 
with higher response rates, longer progression-free survival, 
longer time to treatment failure, and longer nonhospitalized 
survival.17 Tegafur combined with irinotecan was not sig-
nificantly better compared with tegafur alone.18 However, 
when it was combined with cisplatin, significantly longer 
survival was seen than for tegafur alone, with acceptable 
toxicities. This regimen is standard therapy for metastatic 
gastric cancer in Japan.19
Although a large number of chemotherapy regimens have 
been proven in Phase III studies, there is no internationally 
accepted standard of care. Monotherapy with 5-fluorouracil 
or doublets with 5-fluorouracil and cisplatin, irinotecan, or 
an anthracycline, are reasonable options for patients who 
are not candidates for ECF. DCF may be recommended 
in very fit selected patients. Additionally, a preliminary 
updated meta-analysis suggested that chemotherapy com-
binations including irinotecan, oxaliplatin, docetaxel, 
or oral 5-fluouoracil prodrugs, are alternative treatment 
options to cisplatin/5-fluorouracil or cisplatin/5-fluorouracil/
anthracycline-combinations, but do not provide significant 
advantages in overall survival.20 Median time to progression 
after first-line chemotherapy for metastatic gastric cancer 
is typically 3–5 months. No second-line regimen has been 
established, and historically few patients are con  sidered for 
second-line treatment (20%). However, recent data from 
a randomized trial showed that 39%–48% of patients in 
a sequence of chemotherapy including ECF followed by 
FOLFIRI (leucovorin + 5-fluorouracil + irinotecan) and the 
reverse sequence, received a second-line chemotherapy.21 
So far, there are only preliminary data from a Phase III study 
in 40 patients that compared irinotecan monotherapy versus 
best supportive care in second line, demonstrating that irino-
tecan significantly prolongs overall survival (by 50.5 days) 
and improves tumor-related symptoms.22 Some Phase II 
studies has been published; taxanes and irinotecan are the 
most commonly used drugs in this setting, as monotherapy 
or in combined chemotherapy. Responses vary from 0% to 
50%, and time to progression and overall survival has been 
reported to be 3–6 and 6–9 months, respectively. Predictors 
of response have been described, including performance 
status, locally advanced rather than metastatic disease, and 
previous response to first-line therapy.23–26
Molecular targeting agents, alone or in combination with 
chemotherapy, are being tested in the second-line setting.27–29 
Despite the benefits of palliative chemotherapy, and the diver-
sity of chemotherapy regimens, the prognosis of advanced 
gastric cancer remains poor, with a median overall survival 
of 7–10 months. An increased understanding of molecular 
pathways has provided novel targets to treat cancer patients. 
Several molecularly targeted agents are under evaluation in 
patients with advanced gastric cancer.30,31
Bevacizumab combined with chemotherapy (cisplatin 
and irinotecan; oxaliplatin and docetaxel or 5-fluorouracil; 
DCF) has shown promising results in Phase II studies 
including treated and untreated patients (response rates 
63%–71%). However, the main concern arising from these 
trials is toxicity.32–35
A recent update of a Phase III trial including 774 patients 
with advanced gastric cancer who received combined 
chemotherapy (capecitabine/5-fluorouracil + cisplatin) 
with bevacizumab or placebo did not show significant 
differences in overall survival (12.1 versus 10.1 months, 
respectively), although there were significant improve-
ments in progression-free survival and overall response 
rate, with an acceptable safety profile favoring the 
  bevacizumab arm.
Sunitinib has demonstrated disease control rates of 
40%.36 Additionally, preliminary results showed encouraging 
response rates when sunitinib is combined with chemotherapy, 
such as tegafur, capecitabine + cisplatin, or capecitabine + 
oxaliplatin.37–39 Sorafenib in combination with docetaxel and 
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cisplatin showed an encouraging efficacy profile, with toler-
able toxicity (40% partial response rate).40
Cetuximab showed poor response rates (5%) in pretreated 
patients.41 However, in combination with 5-fluorouracil 
and oxaliplatin or irinotecan, a relative risk of 52%–65% 
was seen in previously untreated patients.42–44 Cetuximab 
in combination with docetaxel and cisplatin has a response 
rate of 42%.45
Addition of matuzumab to EOX did not improve tumor 
response or survival in patients with advanced gastric cancer.46 
Most clinical trials using epidermal growth factor recep-
tor tyrosine kinase inhibitors in gastric cancer have shown 
minimal efficacy. Erlotinib had a response rate of 10% in 
previously untreated patients,47 and gefitinib had an 18% 
stable disease rate in previously treated patients.48   Preliminary 
results with lapatinib showed a 7% and 20% partial response 
and stable disease rate, respectively, in untreated patients.49 
A preliminary report of a Phase II study showed that in 
combination with capecitabine, a partial response and stable 
disease were seen in 24% and 34%, respectively.50 The EOX 
regimen with or without panitumumab (REAL-3 study) is 
ongoing,51 with Phase I trials of the combination showing a 
response rate of 65%.52
Pharmacology and pharmacokinetics
Human epidermal growth factor receptor (HER)-2/neu 
(c-erbB-2) is a transmembrane tyrosine kinase receptor, and 
a member of the HER family (HER-1, 2, 3, and 4). HER-2 
functions as an oncogene. Gene amplification induces pro-
tein overexpression in cell membranes, and regulates signal 
transduction in cellular processes, including proliferation, 
differentiation, and cell survival.53,54 Aberrant HER-2 expres-
sion or function has been implicated in breast and gastric 
carcinogenesis, and is evident in other cancer types, including 
ovarian, salivary gland, and prostate and lung cancers.53,55
Trastuzumab is a recombinant humanized anti-HER-2 
MAb (rhuMAb HER-2), directed against the HER-2 extra-
cellular domain.55 Several trastuzumab antitumor activities 
have been described53,56 (see Figure 1):
•	 Blocking of HER-2 receptor cleavage and inhibiting 
dimerization
•	 Increasing receptor destruction by endocytosis
•	 Inhibiting intracellular pathway signaling such as phos-
phoinositide 3-kinase signaling; may indirectly modulate 
proangiogenic and antiangiogenic factors, such as vas-
cular endothelial growth factor production
•	 Inducing G1 phase arrest by inducing the cyclin-
  dependent kinase inhibitor, p27 Kip1
•	 Cytostatic and cytotoxic activity due to immune system 
recruitment by antibody-dependent cell-mediated 
cytotoxicity.
The pharmacokinetics and pharmacodynamics of tras-
tuzumab are not completely understood. Most studies have 
been done in breast cancer patients. Trastuzumab has a 
low systemic clearance (5.15 ± 2.45 mL/kg/day) and a low 
volume of distribution (44 mL/kg). The half-life may vary 
from 1.1 to 28 days with infusions of 10 mg and 500 mg, 
respectively. Half-lives of 2.7, 3.1, 8.8, and 10.4 days were 
found after single doses of 1, 2, 4, and 8 mg/kg, respec-
tively, suggesting that, after trastuzumab receptors become 
saturated, total body clearance becomes linear. Doses of 
4 mg/kg and 8 mg/kg are enough to achieve and maintain the 
serum minimum concentrations (10 µg/mL) needed for anti-
proliferative effects and antibody-dependent cell-mediated 
cytotoxicity.57 Using a loading dose of 4 mg/kg followed by 
2 mg/kg/week, trastuzumab achieves and maintains serum 
minimum concentrations greater than 20 µg/mL.58
No drug interactions have been reported. No monoclonal 
antibody has been found to interact with major molecular 
pharmacokinetic determinants, such as enzymes, drug trans-
porters, or orphan nuclear receptors. Using an initial dose 
of 4 mg/kg followed by 2 mg/kg/week, in combination with 
chemotherapy, the mean peak serum trastuzumab concentra-
tion is similar to that in patients receiving trastuzumab alone 
(101.0 µg/mL at week 8 and 53.4 µg/mL of mean minimum 
concentration).58,59 Elimination pathways are not yet defined, 
and the clinical relevance of trastuzumab kinetic variability is 
unknown. However, trastuzumab elimination seems to depend 
on high serum levels of circulating HER-2 extracellular 
domains, which can be cleaved from the surfaces of cancer 
cells by matrix metalloproteinase and released into the serum. 
Patients with high HER-2 extracellular domain levels tend to 
have a shorter trastuzumab half-life and lower minimum con-
centrations. Patients with four or more metastatic sites have 
faster clearance, independent of HER-2 extracellular domain 
levels. This is influenced little by trastuzumab exposure, and 
trastuzumab steady-state plasma levels are normally much 
higher than those of HER-2 extracellular domain levels.58,59
Efficacy studies in gastric cancer
Overexpression and amplification of HER-2/ErbB2 in gastric 
cancer vary widely, from 6% to 45%.59–64 The largest report 
screened 3883 patients with advanced gastric cancer from 
24 countries, and found 22.1% HER-2-positivity rates in 3807 
evaluated patients. Immunohistochemical and fluorescence in 
situ hybridization concordance was 87.3%. HER-2   positivity 
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was higher in gastroesophageal junction cancers than in gas-
tric cancers (33.2% versus 20.9%, P , 0.001), and higher 
in intestinal cancers than in diffuse/mixed cancers (32.2% 
versus 6.1%/20.4%, P , 0.001). No differences were seen 
between European and Asian countries.65
Early studies in HER-2-positive gastric cancer cell 
lines, showed the growth inhibitory effects of trastuzumab. 
Additionally, when combined with doxorubicin, cisplatin, 
or paclitaxel, it demonstrated increased cytotoxicity, sug-
gesting that a regimen based on these combinations could 
be considered for gastric cancer66 (see Table 1).
Cortés-Funes et al67 have reported the preliminary results 
of a small Phase II study of 21 patients with advanced gas-
tric cancer and HER-2 overexpression/amplification who 
received trastuzumab 8 mg/kg as a loading dose in the first 
cycle, followed by 6 mg/kg every 21 days, and cisplatin 
75 mg/m2 every 21 days. These patients showed response 
rates of 35% and stable disease of 17%. The therapy was 
well tolerated, with no Grade 4 toxicity reported.
Similarly, Egamberdiev et al,68 in a small preliminary 
study of 16 patients with HER-2-positive advanced gastric 
cancer treated with trastuzumab 6 mg/kg and chemotherapy 
(cisplatin, 5-fluorouracil, and leucovorin) every three weeks, 
found an objective response rate of 55% and a median overall 
survival of eight months.
The ToGA study is the first randomized, controlled 
Phase III trial to evaluate the efficacy and safety of trastuzumab 
in advanced HER-2-positive gastric cancer. Five hundred and 
ninety-four patients received either trastuzumab in combina-
tion with 5-fluorouracil/capecitabine and cisplatin or chemo-
therapy alone. The chemotherapy group (control arm) received 
capecitabine 1000 mg/m² twice a day for 14 days or continuous 
infusion of 5-fluorouracil 800 mg/m²/day on days 1–5 of each 
cycle, plus cisplatin 80 mg/m² on day 1 every three weeks. 
The experimental arm received the same chemotherapy plus 
trastuzumab 8 mg/kg on day 1 of the first cycle, followed by 
6 mg/kg every three weeks. The final report at 18.6 months of 
HER2
HER1,2,3 or 4
Trastuzumab
P
P P
Blocks HER2 dimerization binding ECD IV
Activation of antibody dependent cell-
mediated cytotoxicity tumor  cell lysis
Extracellular effects
Intracellular effects
Amplified number HER2 genes on chromosome 17
Transcription
stop proliferation G1 phase arrest 
Antiangiogenic effect (HER-family  receptor blockade 
leads to reductions in VEGF)  
Receptor down-regulation through endocytosis
Inhibits signaling (PI3K pathway ) 
Pro-apoptosis and proliferation arrest
Figure 1 Antitumor effects of trastuzumab.
Abbreviations: eCD, extracellular domain; veGF, vascular endothelial growth factor; Pi3K, phosphoinositide 3-kinase.
Table 1 Trastuzumab in gastric cancer: Preclinical and clinical 
trials
Authors Type of study n Comments
Gong et al66 Preclinical 
T + D
Cell lines Antitumor activity
Cortés-Funes et al67 Phase ii 
T + C
21 PR 35% 
SD 17%
egamberdiev et al68 Phase ii 
T + C
16 OR 55% 
OS 8 months
van Cutsem e et al69  Phase iii 
T + Cap/5-FU 
CT alone
597 OS (P = 0.0048,  
death risk 
reduction by 26%) 
13.5 months 
11.1 months
Abbreviations: T, trastuzumab; C, cisplatin; D, doxorubicin; Cap, capecitabine; 
CT, chemotherapy; PR, partial response; SD, stable disease; OS, overall survival; 
OR, objective response; 5-FU, 5-fluorouracil.
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median follow-up for the experimental arm and 17.1 months 
for the control arm showed better median survival with the 
combination (13.8 versus 11.1 months, P = 0.0046; HR 
0.74, 95% CI: 0.60–0.91) with a 26% reduction in risk of 
death. Progression-free survival was 6.7 versus 5.5 months 
(P = 0.0002), and tumor response (including complete and 
partial response) was 47% versus 35% (P = 0.0017) with the 
addition of trastuzumab versus chemotherapy alone. Toxicity, 
including cardiac adverse events, was similar in both groups. 
More than 40% of patients in both groups received second-line 
treatment. Subgroup analysis for survival favored trastuzumab 
throughout (site of tumor, performance status, fluoropyrimidine 
used, histology, age, region, prior gastrectomy, and number 
of metastatic sites). Patients with high immunohistochemi-
cal positivity for HER-2 had a trend for better survival in the 
preplanned analysis (16 months) with trastuzumab compared 
with chemotherapy alone (11.8 months).69 This finding sug-
gests that levels of HER2 protein expression predict response 
to trastuzumab, similar to what has been described in metastatic 
breast cancer. Therefore, patients with advanced gastric cancer 
and these tumor characteristics should be offered trastuzumab 
plus chemotherapy as a treatment option.
Safety and tolerability
The most common adverse events with trastuzumab are 
infusion-related reactions (fever, rigors, chills, nausea, dyspnea, 
and hypotension), present in about 40% of patients with the 
first dose and in 5% with subsequent doses.70 Myelosuppres-
sion, nausea, and vomiting are rare, and alopecia has not been 
reported with monotherapy. However, quantifying the contri-
bution of trastuzumab to these side effects is difficult when 
it is given in combination with chemotherapy.71 In the ToGA 
trial, serious adverse events were reported in 32% of patients 
treated with trastuzumab plus chemotherapy and 28% in the 
chemotherapy alone group. Treatment-related mortality was 3% 
and 1% in the experimental and control arm, respectively.
Special attention has focused on the cardiotoxicity of 
trastuzumab. Sporadic cases of congestive heart failure were 
reported in the early trials. However, an association between 
impairment of left ventricular ejection fraction and trastu-
zumab was more evident when given in combination with 
chemotherapy. The pivotal study in breast cancer showed 
cardiac toxicity in 27% of patients when trastuzumab was 
combined with anthracyclines, in 13% when it was combined 
with paclitaxel, and in 5% with trastuzumab alone.71 The 
ToGA trial reported cardiac event rates of 6%.70
Postmarketing surveillance for trastuzumab has reported 
that 62 of 25,000 (0.002%) patients have had serious 
adverse events (hypersensitivity reactions, infusion-related 
reactions, and pulmonary events). Adult respiratory distress 
syndrome, anaphylaxis, and death within 24 hours of a 
trastuzumab infusion were reported. Fatal events occurred 
mostly in patients with pre-existing pulmonary dysfunction, 
so these patients should be treated with caution, and 
trastuzumab should be discontinued if severe infusion-related 
reactions occur.58,72 A Phase IV trial is currently underway to 
evaluate the efficacy and safety of trastuzumab in patients 
with advanced HER-2 gastric cancer.
Patient-focused perspectives
Ideally, any gain in survival should also be accompanied by 
an improvement in or at least stable quality of life. Assess-
ment of quality of life with trastuzumab therapy has been 
studied in breast cancer patients, with favorable results. There 
are no available data in patients with gastric cancer as yet. 
Osoba et al73 found that patients treated with trastuzumab 
plus chemotherapy had significantly better improvement in 
quality of life (51%) than patients treated with chemotherapy 
alone (36%).
More recently, Rugo et al74 demonstrated that patients 
treated with chemotherapy and trastuzumab versus chemother-
apy alone had more improvement in quality of life (51% versus 
36%, respectively). Improved physical, role functioning, and 
fatigue were also seen in the combined therapy arm.
Discussion
Gastric cancer is an aggressive disease with a high mortal-
ity rate, and despite recent progress in diagnosis, surgical 
techniques, chemotherapy, and radiotherapy, the prognosis 
remains poor. Advanced or metastatic gastric cancer consti-
tutes the majority of patients in Western clinical practice. 
Chemotherapy has been considered the standard, with the 
significant advantages of increased survival, symptom con-
trol, and quality of life, compared with best supportive care 
alone. Trastuzumab is the first monoclonal antibody that 
has been shown to prolong life in patients with a malignant 
epithelial condition. In HER-2 breast cancer patients, its 
impact has been considerable. For advanced gastric cancer 
patients, trastuzumab is the first biological therapy that has 
showed a survival benefit. The ToGA trial included patients 
selected for treatment according to molecular profile. Encour-
agingly, trastuzumab in combination with chemotherapy 
showed a median survival of 13.8 months. Trastuzumab is a 
reasonable treatment option for patients with HER-2-positive 
advanced gastric cancer, although only approximately 20% 
of patients would be potential candidates. Some patients with 
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HER-2-positive disease demonstrated primary or secondary 
resistance. Mechanisms of resistance and potential strate-
gies to overcome these have been extensively researched 
in breast cancer, including loss of phosphatase and tensin 
homolog protein, activating mutations in the gene encod-
ing phosphatidylinositol kinase-3, and increased signaling 
through other receptors (epithelial growth factor receptor 
and insulin-like growth factor-1 receptor). Lapatinib, the dual 
HER-2/epithelial growth factor receptor inhibitor, prolongs 
time to progression in patients with trastuzumab-resistant 
HER-2-positive breast cancer,75,76 and warrants evaluation in 
trastuzumab-resistant HER-2-positive gastric cancer.
Two Phase II trials, one combining chemotherapy 
(capecitabine and oxaliplatin) and targeted therapy (bevaci-
zumab and trastuzumab), and the other with trastuzumab in 
combination with tegafur and cisplatin in advanced gastric 
cancer are planned. Additionally, two Phase II studies evalu-
ating lapatinib in combination with capecitabine and weekly 
paclitaxel in first-line and second-line settings, respectively, 
in advanced gastric cancer are open to recruitment.
Further research is needed to evaluate the efficacy of 
trastuzumab as monotherapy, maintenance treatment, and 
second-line therapy for advanced gastric cancer. Moreover, 
trastuzumab should be integrated into curative treatment 
trials for patients with gastric cancer, such as perioperative 
or postoperative therapy.
With a better understanding of gastric cancer epidemi-
ology and an ability to categorize it into distinct clinical and 
pathologic entities, improvement in gastric cancer therapy is 
expected. Moreover, by improving our knowledge of gastric 
cancer biology and signaling pathways, integration of tar-
geted therapies has become possible and promising. Better 
selection of patients for a particular ther  apy will significantly 
improve treatment paradigms for this deadly disease, with 
the possibility of also improv  ing patient survival. Several 
clinical trials with targeted therapies, including bevacizumab, 
cetuximab, panitumumab, and lapatinib in combination with 
conventional chemotherapy regimens, are currently ongo-
ing, which may help to increase our armamentarium against 
gastric cancer.
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